Therapeutic options for HIV-associated lymphomas

Michele Spina, Annunziata Gloghini, Umberto Tirelli, Antonino Carbone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Importance of the field: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. Areas covered in this review: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas. What the reader will gain: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks. The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients. Take home message: HIV-associated lymphomas still represent a relevant field of clinical research. Standard methodologies for therapy in this patient population have yet to be established. However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.

Original languageEnglish
Pages (from-to)2471-2481
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number15
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Lymphoma
HIV
Primary Effusion Lymphoma
Tissue Banks
Therapeutics
Drug Therapy
Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Natural History
Population
HIV Infections
Mouth
Prospective Studies
Research
Neoplasms

Keywords

  • AIDS-related lymphomas
  • HIV-associated lymphomas
  • KSHV/HHV8-associated lymphomas
  • Therapeutic options

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Therapeutic options for HIV-associated lymphomas. / Spina, Michele; Gloghini, Annunziata; Tirelli, Umberto; Carbone, Antonino.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 15, 10.2010, p. 2471-2481.

Research output: Contribution to journalArticle

Spina, Michele ; Gloghini, Annunziata ; Tirelli, Umberto ; Carbone, Antonino. / Therapeutic options for HIV-associated lymphomas. In: Expert Opinion on Pharmacotherapy. 2010 ; Vol. 11, No. 15. pp. 2471-2481.
@article{155cdbdfc35a4495af9d9ba866578b44,
title = "Therapeutic options for HIV-associated lymphomas",
abstract = "Importance of the field: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. Areas covered in this review: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas. What the reader will gain: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks. The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients. Take home message: HIV-associated lymphomas still represent a relevant field of clinical research. Standard methodologies for therapy in this patient population have yet to be established. However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.",
keywords = "AIDS-related lymphomas, HIV-associated lymphomas, KSHV/HHV8-associated lymphomas, Therapeutic options",
author = "Michele Spina and Annunziata Gloghini and Umberto Tirelli and Antonino Carbone",
year = "2010",
month = "10",
doi = "10.1517/14656566.2010.502528",
language = "English",
volume = "11",
pages = "2471--2481",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "15",

}

TY - JOUR

T1 - Therapeutic options for HIV-associated lymphomas

AU - Spina, Michele

AU - Gloghini, Annunziata

AU - Tirelli, Umberto

AU - Carbone, Antonino

PY - 2010/10

Y1 - 2010/10

N2 - Importance of the field: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. Areas covered in this review: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas. What the reader will gain: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks. The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients. Take home message: HIV-associated lymphomas still represent a relevant field of clinical research. Standard methodologies for therapy in this patient population have yet to be established. However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.

AB - Importance of the field: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. Areas covered in this review: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas. What the reader will gain: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks. The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients. Take home message: HIV-associated lymphomas still represent a relevant field of clinical research. Standard methodologies for therapy in this patient population have yet to be established. However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.

KW - AIDS-related lymphomas

KW - HIV-associated lymphomas

KW - KSHV/HHV8-associated lymphomas

KW - Therapeutic options

UR - http://www.scopus.com/inward/record.url?scp=77957033810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957033810&partnerID=8YFLogxK

U2 - 10.1517/14656566.2010.502528

DO - 10.1517/14656566.2010.502528

M3 - Article

VL - 11

SP - 2471

EP - 2481

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -